LARAMIE, Wyo.— Work is underway at the Wyoming State Veterinary Laboratory to add a biohazard facility that will focus on the nasty diseases found in some Wyoming wildlife, like the plague and rabies. Director William Laegreid said the upgraded "biosafety level 3" laboratory will allow veterinarians to keep the main facility open when an animal shows up with a... » Read More
The world’s largest drug company, Pfizer, has handled mergers badly, invented too few drugs and left its reputation in disrepair after two criminal cases. And that is the assessment of its own chief executive. The NYT talks to Pfizer CEO Jeffrey Kindler.
But, oh! The irony. At a meeting designed to convince the Street the company is well on its way to correcting a major manufacturing problem, a simple technical glitch keeps executives from conveying that message to a broader, off-site audience.
A federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property. The NYT reports.
More than a week after President Obama signed the sweeping new health care law, which will eventually provide insurance coverage for 32 million uninsured Americans, many of us are still scratching our heads. What just happened? And how and when will we start feeling its effect? the NYT explains.
Electronic health records are a good first step, but represent only one aspect of how IT can improve America’s healthcare system by making it seamless and safer, writes Chris Begley, Chairman & CEO, Hospira, Inc.
You need to buy the paper edition for $5 or subscribe to the website to see it for yourself, but Barron's has put only one biopharma honcho on its annual list of the world's top-30 CEOs.
Vivus announced this morning that an FDA advisory committee is tentatively scheduled to take a look at its diet drug Qnexa on Thursday, July 15th.
One of the many things I think is great about Twitter is the direct contact it gives me with a handful of biopharma reporters who are using it.
Carl Icahn, reputed to be a late-riser, woke up to good news and bad news today.
Shares of Teva Pharmaceutical Industries are once again trading at an historic high. But they might not be there today if it weren’t for a tragedy.
Hospitals and drug makers, which supported the final healthcare legislation, would be clear beneficiaries, analysts say, even if the outlook for insurers was less certain, the NY Times reports.
The 800-pound gorilla of one industry has beaten the 800-pound gorilla of another. Teva CEO Shlomo Yanai took on Pfizer CEO Jeff Kindler and won.
Take our quiz and see how much you know about products that were recalled to keep consumers safe.
Speaker Pelosi is as good as it gets in wrestling votes for legislation she favors. She is the female version of that titan, Tip O'Neill (D. Mass.) who famously said, "All politics is local." But as good as she is, the Speaker seems to have come up short with the necessary votes to get the Senate version of the health care bill passed in the House of Representatives.
I can hear the commercial now. “Underarm protection that literally makes you feel more like a man.”
With states squeezing payments to providers even as the economy fuels explosive growth in enrollment, patients are finding it increasingly difficult to locate doctors and dentists who will accept Medicaid coverage. The New York Times reports.
Of course, I'm off the day all heck breaks loose on the beat and stocks are making big moves all over the place.
President Obama is going all in on the health care plan. He postponed an overseas trip to be on hand for a hoped for vote on the plan this coming Friday.
Tomorrow is the day the agency is scheduled to announce if the first once-a-week diabetes treatment, a rejiggered version of the now twice-a-day Byetta, can come to market.
A unit of Johnson & Johnson, just months after saying it was phasing out an artificial hip implant because of slowing sales, has warned doctors that the device appears to have a high early failure rate in some patients.